{"id":308,"date":"2026-06-17T05:33:00","date_gmt":"2026-06-17T09:33:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=308"},"modified":"2026-05-16T13:38:25","modified_gmt":"2026-05-16T17:38:25","slug":"how-pharma-companies-monitor-ai-generated-drug-mentions-before-the-fda-does","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/how-pharma-companies-monitor-ai-generated-drug-mentions-before-the-fda-does\/","title":{"rendered":"How Pharma Companies Monitor AI-Generated Drug Mentions Before the FDA Does"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/drugchatter.com\/insights\/wp-content\/uploads\/2026\/05\/image-60.png\" alt=\"\" class=\"wp-image-461\" srcset=\"https:\/\/drugchatter.com\/insights\/wp-content\/uploads\/2026\/05\/image-60.png 1024w, https:\/\/drugchatter.com\/insights\/wp-content\/uploads\/2026\/05\/image-60-300x164.png 300w, https:\/\/drugchatter.com\/insights\/wp-content\/uploads\/2026\/05\/image-60-768x419.png 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">When a patient types &#8216;Is Ozempic safe for people with pancreatitis?&#8217; into ChatGPT, the answer they receive is not written by a physician, reviewed by a pharmacist, or cleared by the FDA. It is generated by a large language model trained on web data that may be months or years out of date, scraped from sources that range from peer-reviewed journals to Reddit threads and patient forums.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">What Novo Nordisk, Eli Lilly, AstraZeneca, and dozens of other pharmaceutical manufacturers are realizing is that this matters \u2014 not just for patient safety, but for brand equity, adverse event surveillance, and regulatory exposure. The conversation between a patient and an AI chatbot has become a new front in pharmaceutical reputation management, and most brand teams are not yet tracking it.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That is starting to change.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Why AI Search Has Become a Pharma Reputation Problem<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Search behavior has shifted faster than most pharmaceutical marketing teams anticipated. In 2022, a patient researching a drug might type a query into Google, scan the top results, and read a WebMD page or a clinical trial summary. In 2025, a meaningful and growing share of those patients go directly to ChatGPT, Perplexity, Google&#8217;s AI Overviews, or Claude and ask their question in natural language \u2014 and get a single synthesized answer rather than a list of links.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The consequences for pharmaceutical brands are structural. In traditional search, a company could track where its product pages ranked, run paid campaigns, and monitor which third-party sites were shaping the narrative. In AI search, the model absorbs all of that content and synthesizes it into an answer that may accurately reflect the drug&#8217;s label \u2014 or may not.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">LLMs hallucinate. They also embed bias. A model trained on data from 2023 may not reflect a label change the FDA approved in 2024. A model with heavy Reddit representation in its training corpus may weight patient anecdotes about side effects more heavily than clinical trial data. A model that was fine-tuned on cost-efficiency messaging may suggest generic alternatives in contexts where branded drugs have meaningfully different pharmacokinetics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">None of this is hypothetical. It is happening now, and pharmaceutical companies that are not tracking it are flying blind.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How Patients Actually Ask AI About Their Medications<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The queries patients send to AI systems are not the clean, categorical questions that appear in clinical literature. They are conversational, context-heavy, and often laden with misinformation the patient already believes. Common query patterns include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>&#8216;Can I take Humira and ibuprofen at the same time?&#8217;<\/li>\n\n\n\n<li>&#8216;Why is my doctor prescribing Keytruda off-label for my cancer type?&#8217;<\/li>\n\n\n\n<li>&#8216;Is the generic version of Eliquis the same thing?&#8217;<\/li>\n\n\n\n<li>&#8216;What happens if I miss a dose of Jardiance?&#8217;<\/li>\n\n\n\n<li>&#8216;I heard Ozempic causes thyroid cancer \u2014 is that true?&#8217;<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Each of these queries is a pharmacovigilance signal, a brand perception data point, and a potential patient safety moment \u2014 all at once. The AI answer shapes the patient&#8217;s next action: whether they call their physician, skip a dose, demand a generic switch, or stop the medication entirely.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What LLMs Actually Say About Branded Drugs<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The variance across AI systems is substantial. In structured testing environments, ChatGPT-4o, Gemini 1.5 Pro, Claude 3.5, and Perplexity AI have been shown to produce meaningfully different answers to identical drug-related queries. One system may accurately represent the FDA-approved indication for a drug while another leads with off-label cautions sourced from forum posts. One may cite the branded name while another defaults to the generic equivalent without acknowledgment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The pattern is not random. It reflects each model&#8217;s training data, fine-tuning choices, and retrieval-augmented generation (RAG) sources. Perplexity, which retrieves real-time web sources, tends to reflect whatever dominates current search rankings \u2014 which can include news coverage of litigation or FDA warning letters. ChatGPT, without real-time retrieval enabled, reflects its training cutoff and may present outdated label information as current.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For a pharmaceutical brand team, this is not an abstract technology concern. It is a question of whether a patient asking a reasonable clinical question receives accurate information about their medication.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Can AI Hallucinations Trigger FDA Regulatory Risk?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA has not yet issued formal guidance on AI-generated drug content, but the regulatory framework for drug misinformation is not new \u2014 and it does not have an AI exception.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under 21 CFR Part 202 and related guidance, pharmaceutical companies have an obligation to ensure that promotional and informational content about their products is truthful, not misleading, and fairly balanced. The agency&#8217;s longstanding position, reinforced through warning letters to companies ranging from Duchesnay to Amag Pharmaceuticals, is that context matters: if a drug company is aware that misinformation about its product is circulating, and takes actions that might amplify it, that creates exposure.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What the FDA&#8217;s History of Warning Letters Tells Us About AI Risk<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Between 2014 and 2024, the FDA&#8217;s Office of Prescription Drug Promotion issued hundreds of warning letters and untitled letters to pharmaceutical companies for promotional content that overstated efficacy, minimized safety risks, or made comparative claims unsupported by clinical data. The most common violations involved social media content \u2014 company-sponsored posts on Facebook, Twitter, and Instagram that cherry-picked data or buried adverse event disclosures.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The AI context is different, because the company is not generating the content. But regulatory attorneys who work in pharmaceutical promotional compliance draw a distinction between generating misinformation and responding to it. If a brand team discovers that ChatGPT is systematically telling patients that their drug has no risk of liver toxicity when the label includes a black box warning, the question of whether they have an obligation to act \u2014 and how to act \u2014 is not settled.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">What is settled is that the FDA can and does act on post-market safety signals derived from sources other than formal adverse event reports. Social media monitoring is already an established input to pharmacovigilance programs at major manufacturers. AI output monitoring is the logical next extension.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does an AI Hallucination About Drug Safety Count as a Reportable Adverse Event?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This is the question pharmaceutical regulatory affairs teams are actively debating, and the answer is genuinely unsettled. The FDA&#8217;s adverse event reporting requirements under 21 CFR 314.81 require manufacturers to report serious and unexpected adverse experiences of which they become aware. The phrase &#8216;become aware&#8217; has been interpreted broadly in enforcement history.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If a pharmaceutical company systematically monitors AI outputs and discovers that a large language model is advising patients to discontinue a medication abruptly in a context where abrupt discontinuation creates clinical risk, and a patient subsequently experiences harm correlated with that behavior, the question of company knowledge and response becomes material.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Several large manufacturers, including AstraZeneca and Johnson &amp; Johnson, have expanded their pharmacovigilance programs to include social media listening platforms \u2014 tools that scan Reddit, X (formerly Twitter), patient forums, and disease communities for adverse event signals. AI output monitoring fits into that same operational framework.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Off-Label AI Mentions and the Promotional Compliance Boundary<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Off-label drug use is legal for physicians but heavily restricted in pharmaceutical promotion. The FDA prohibits companies from marketing drugs for uses not included in their approved labeling. This restriction does not prevent physicians from prescribing off-label, but it constrains what a company can say publicly about off-label uses.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">LLMs regularly discuss off-label drug use. When a patient asks Claude or ChatGPT whether a drug used for one indication might help with a different condition, the model draws on its training data, which includes scientific literature, case reports, and clinical commentary that the pharmaceutical company is prohibited from citing in its own marketing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This creates an asymmetric information environment. The AI discusses what the company cannot. The company&#8217;s brand team needs to know what the AI is saying \u2014 even if they cannot directly counter it \u2014 because the content shapes physician and patient perception of the drug&#8217;s clinical profile.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">How Often Does Claude Mention Ozempic vs. Wegovy \u2014 and Does It Matter?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ozempic (semaglutide, Novo Nordisk) and Wegovy (semaglutide, Novo Nordisk) are the same molecule at different doses, approved for different indications \u2014 type 2 diabetes management and chronic weight management, respectively. The distinction matters both clinically and commercially. Wegovy carries a higher price point and different insurance coverage dynamics. Prescribers and patients who confuse the two products create adherence problems and formulary management challenges.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In structured AI probe testing, the two drugs are frequently conflated. Models that lack strong entity disambiguation tend to answer questions about one product using information sourced from coverage of the other. This is not a trivial error: a patient asking about Ozempic&#8217;s coverage for weight loss may receive an answer about Wegovy&#8217;s clinical trial data, or vice versa.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For Novo Nordisk&#8217;s brand team, tracking these conflation patterns across AI platforms is a competitive intelligence and patient safety function simultaneously. The frequency with which models correctly distinguish the two products, cite the right indication, and avoid cross-contaminating the clinical narratives is a measurable brand health metric.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Share of AI Voice: Branded Drugs vs. Generics in LLM Responses<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Brand managers in pharmaceutical have tracked share of voice in traditional media for decades \u2014 the percentage of coverage in a given category that mentions their drug versus a competitor&#8217;s. AI search creates a new version of this metric: share of AI voice.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Share of AI voice measures how often a specific branded drug appears in LLM responses to category-level queries. When a patient asks &#8216;What are the best GLP-1 medications for weight loss?&#8217;, how often does the model mention Wegovy versus Zepbound versus Saxenda? When a physician asks about TNF inhibitors for rheumatoid arthritis, does the model lead with Humira, Enbrel, or a generic biosimilar?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The dynamics here differ from paid search. In Google, Eli Lilly can buy the keyword &#8216;GLP-1 medication&#8217; and ensure Zepbound appears prominently. In ChatGPT or Claude, there is no sponsored placement. The model&#8217;s answer reflects its training data and retrieval logic. A company that has invested heavily in peer-reviewed publication, physician education, and high-quality online content about its drug should \u2014 in theory \u2014 see that investment reflected in AI share of voice. But the relationship is not linear, and it is not transparent.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8216;Pharmaceutical companies spent $6.58 billion on direct-to-consumer advertising in the United States in 2023. None of that spending directly influences what a large language model tells a patient when they ask about a medication.&#8217; \u2014 IQVIA Institute for Human Data Science, 2024 Medicine Spending and Affordability Report<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">Do LLMs Recommend Generic Drugs More Often Than Branded Alternatives?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The available evidence suggests yes, with significant variation by model and query type. Models trained on general web data absorb substantial content from cost-focused health journalism, patient advocacy forums, and pharmacy benefit management communications \u2014 all of which tend to favor generic substitution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When a patient asks &#8216;Is there a cheaper version of Eliquis?&#8217;, the model&#8217;s answer reflects the clinical and commercial reality that apixaban is off-patent in many markets and that generic versions have received FDA approval. The branded name&#8217;s marketing investment does not appear in that answer unless it appears in the model&#8217;s training data in a way that is weighted appropriately.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For pharmaceutical companies with branded drugs facing patent cliffs, this is a material concern. The AI conversation is already occurring. Patients are asking. The question is what the model is telling them \u2014 and whether the answer is clinically accurate.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Tracking AI Brand Mentions: What Pharmaceutical Companies Are Actually Doing<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The most sophisticated pharmaceutical brand monitoring programs now include systematic AI output tracking as a distinct data stream alongside traditional media monitoring, social listening, and physician survey data.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The operational structure varies by company size and sophistication. At large manufacturers like Pfizer, AstraZeneca, and Bristol Myers Squibb, AI monitoring tends to sit at the intersection of the brand team, the regulatory affairs group, and the medical information function. At mid-sized specialty pharma companies, it is more commonly a brand team responsibility with regulatory oversight.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How Eli Lilly and Novo Nordisk Monitor AI Mentions of Their Products<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Novo Nordisk, whose GLP-1 portfolio includes Ozempic, Wegovy, and Victoza, operates in one of the most intensely discussed therapeutic categories in AI search. Queries about GLP-1 medications, semaglutide, weight loss drugs, and diabetes management generate enormous AI search volume. The company&#8217;s digital health and brand teams track AI responses across major platforms using structured query sets that probe for accuracy, brand representation, safety language, and competitive framing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Eli Lilly, whose Zepbound (tirzepatide) competes directly with Novo Nordisk&#8217;s GLP-1 products, faces an analogous monitoring challenge. Lilly has also expanded its patient insights infrastructure to capture conversational AI data as a signal for emerging clinical questions and patient concerns.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Neither company has disclosed detailed information about its AI monitoring methodology publicly. But the operational expansion is visible in hiring patterns, vendor relationships, and the growth of digital health intelligence functions within both organizations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What Platforms to Monitor: ChatGPT, Gemini, Claude, and Perplexity<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Each major AI platform has distinct characteristics that affect how drugs are represented.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ChatGPT (OpenAI):<\/strong> The largest consumer AI platform by user base. Without real-time retrieval, its responses reflect its training cutoff. With retrieval enabled, it ingests current web content. The model&#8217;s medical response quality has improved substantially across versions, but hallucination rates for specific drug interactions remain non-trivial. OpenAI&#8217;s &#8216;memory&#8217; feature, which retains user context across sessions, creates personalization dynamics that pharmaceutical monitoring programs have not yet fully addressed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gemini (Google):<\/strong> Integrated into Google Search through AI Overviews, Gemini represents the largest surface area for AI-generated drug information because it intercepts queries that previously went to organic search results. A patient who previously would have clicked through to the FDA&#8217;s drug label page or a clinical pharmacy site may now receive an AI-synthesized answer before they see any traditional results. Google has implemented specific restrictions on AI Overviews for medical and health queries, but the restrictions are not comprehensive.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Claude (Anthropic):<\/strong> Tends to be more conservative in medical contexts than some competing models, with a higher rate of recommending physician consultation and citing uncertainty. This conservative posture has different implications for pharmaceutical brand monitoring \u2014 a model that consistently says &#8216;I cannot provide specific medical advice&#8217; is not a reputation risk in the same way as a model that provides confident but incorrect clinical claims.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Perplexity:<\/strong> Retrieves real-time sources and cites them explicitly, which creates a different monitoring challenge. The reputation risk here is less about hallucination and more about source selection \u2014 which sites, journals, or news outlets Perplexity chooses to pull from when synthesizing a drug-related answer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Tools for Pharma AI Brand Monitoring: What&#8217;s Available Now<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A small but growing category of specialized tools has emerged to help pharmaceutical companies track AI-generated drug content. <a href=\"https:\/\/www.drugchatter.com\/monitoring\/\">DrugChatter<\/a> offers structured monitoring of drug mentions across AI platforms, enabling brand teams to track share of voice, accuracy metrics, and sentiment patterns across ChatGPT, Gemini, Claude, and other systems. DrugPatentWatch provides patent and exclusivity intelligence that, combined with AI monitoring, helps companies anticipate when generics will enter AI-generated responses as legitimate alternatives.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Legacy social listening platforms \u2014 Brandwatch, Sprinklr, Talkwalker \u2014 have begun adding AI output monitoring capabilities, though their primary architecture was built for social media and the adaptation to LLM output is uneven. Purpose-built pharmaceutical intelligence platforms tend to offer deeper query structuring and regulatory flagging capabilities.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Why ChatGPT Gets Drug Side Effects Wrong \u2014 and Why It Matters<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The error modes for LLMs on drug side effect queries fall into several distinct categories, each with different implications for pharmaceutical companies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Training Data Staleness and Label Changes<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FDA drug labels change. Black box warnings are added. Contraindications are updated. Dosing recommendations shift based on post-market surveillance data. A model trained on data from 18 months ago may present outdated label information as current fact.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Ozempic thyroid cancer risk is a useful example. The drug carries an FDA-mandated warning about a risk of thyroid C-cell tumors observed in rodent studies, with an acknowledgment that the relevance to humans is unknown. This warning language has evolved across label updates. A model that absorbed an earlier version of the label may present the warning differently from the current version \u2014 in either direction, either understating or overstating the risk relative to current FDA language.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Frequency and Severity Distortion<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">LLMs frequently misrepresent the frequency and severity of adverse events. A side effect listed as occurring in 1-5% of patients in clinical trials may be described as &#8216;common&#8217; by a model that absorbed multiple patient forum posts where people who experienced the side effect are discussing it \u2014 creating a selection bias where rare-but-discussed events appear more prevalent than they are.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This distortion runs in both directions. A model that absorbed primarily industry-sponsored content may underweight adverse event frequencies. A model that absorbed primarily patient advocacy and litigation-adjacent content may overweight them. Neither distortion is accurate, and both create patient decision-making problems.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Drug Interaction Hallucination: A Clinical Safety Concern<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Drug-drug interaction queries are among the most clinically significant question types that patients bring to AI systems. They are also among the most reliably problematic. LLMs have demonstrated consistent failure modes on complex interaction questions \u2014 citing interactions that do not exist, missing interactions that do, and providing incorrect severity classifications for interactions that are real.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A 2024 study published in JAMA Internal Medicine evaluated ChatGPT&#8217;s responses to 100 drug interaction queries and found that the model provided correct interaction information in approximately 60% of cases, with errors split roughly equally between false positives (citing non-existent interactions) and false negatives (missing real interactions). The performance was meaningfully below that of dedicated clinical drug interaction databases like Lexicomp or Micromedex.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For a pharmaceutical company, the clinical risk here is patient-level. For the regulatory risk, the question is whether the company&#8217;s brand is attached to incorrect interaction information in AI-generated responses and what that implies for labeling compliance and post-market commitment.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Patient Sentiment in AI: The New Voice of the Customer<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Voice-of-the-customer (VOC) research in pharmaceutical has traditionally relied on patient surveys, physician interviews, social media listening, and analysis of patient support call center data. AI search creates a new and unusually rich data source: the questions patients are actually asking in real time, without the social desirability bias that affects survey responses.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What Patient Queries in AI Reveal That Surveys Miss<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">When a patient types a question into an AI system, they are not performing for a researcher. They are asking what they actually want to know. This produces a different signal than a survey administered by a brand team or a market research firm with a stake in the answer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The questions patients ask about their medications in AI systems tend to cluster around four themes that conventional research often undercaptures:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Practical administration questions (&#8216;Can I take this with food?&#8217; &#8216;What do I do if I miss a dose?&#8217;)<\/li>\n\n\n\n<li>Social stigma and disclosure (&#8216;Will my employer know I&#8217;m taking this?&#8217;)<\/li>\n\n\n\n<li>Cost and access concerns (&#8216;Why did my insurance stop covering this?&#8217;)<\/li>\n\n\n\n<li>Unresolved safety fears (&#8216;I read that this drug causes cancer \u2014 is my doctor hiding something?&#8217;)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The last category is the most actionable for pharmaceutical brand and medical affairs teams. A pattern of AI queries expressing fear about a specific safety signal \u2014 particularly one that is not supported by clinical evidence \u2014 is an early warning indicator for patient nonadherence, negative press coverage, and potentially litigation-driven narratives.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How Reddit AI Citations Shape What LLMs Believe About Drugs<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Reddit is one of the most heavily indexed sources on the internet, and its pharmaceutical-related communities are substantial. The r\/diabetes and r\/diabetes_t2 communities have hundreds of thousands of members sharing medication experiences. The r\/Ozempic community had over 50,000 active subscribers by late 2024. The r\/ChronicPain and r\/ChronicIllness communities generate high volumes of medication-related posts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Because LLMs train on web data, and because Reddit content is indexed and heavily represented in that data, patient forum narratives about drug experiences are embedded in the models&#8217; responses. A drug that has a strong positive narrative on Reddit \u2014 frequent reports of efficacy, manageable side effects, and positive patient outcomes \u2014 may receive a more favorable AI-generated treatment than a drug with equivalent clinical data but a more negative patient forum presence.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This is not a conspiracy. It is a property of how language models are built. But it means that pharmaceutical companies have an indirect interest in the health of patient communities around their products \u2014 not to manipulate them, but to understand what signal those communities are sending and how that signal is shaping AI-generated answers.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Physician Perception and AI: Are HCPs Using AI for Drug Information?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The answer is yes, at rates that have surprised some pharmaceutical market research teams. A 2024 survey by Doceree found that over 65% of U.S. physicians reported using AI tools for clinical reference at least occasionally, with drug interaction checks and dosing queries among the most common use cases. The tools used range from consumer AI systems like ChatGPT to purpose-built clinical AI systems like Amboss or UpToDate&#8217;s AI features.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For pharmaceutical medical affairs teams, this creates a physician education challenge that is structurally different from the traditional peer-to-peer and key opinion leader model. If a cardiologist is using ChatGPT to check whether a specific combination of heart failure medications creates interaction risk, and the model&#8217;s answer is wrong, the failure point is not in the pharma company&#8217;s medical education program \u2014 it is in the AI system&#8217;s training data. But the clinical consequence and the brand association remain with the manufacturer.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">AI Search Optimization for Pharma Brands: What Actually Works<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The question pharmaceutical digital teams are beginning to ask is whether they can influence what AI systems say about their products \u2014 and if so, how. The answer is nuanced, and the analogy to traditional SEO is imperfect.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does Publishing High-Quality Content Improve AI Drug Mentions?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The evidence suggests that content quality and authority do influence AI-generated responses, but with significant lag and uncertainty. Models with retrieval-augmented generation, like Perplexity, will reflect high-quality indexed content more quickly than models that rely on static training data. For static-training models, the influence is felt only at retraining cycles, which may occur quarterly or annually.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The practical implication for pharmaceutical companies is that investment in high-quality, medically accurate, SEO-optimized content about their products \u2014 published on authoritative domains, structured for machine readability, and updated regularly to reflect label changes \u2014 is likely to improve AI representation over time. It is not a guaranteed input-output relationship, but it is a better strategy than ignoring the question.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can Pharmaceutical Companies Influence AI Drug Recommendations Directly?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Direct influence is limited and, in some cases, prohibited. OpenAI, Anthropic, and Google do not sell placement in AI-generated answers in the way that Google sells paid search positions. Attempts to manipulate AI outputs through astroturfing, fake review seeding, or paid content promotion designed to skew training data would raise both legal and ethical concerns under FTC guidelines on endorsements and testimonials, as well as FDA promotional regulations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">What companies can legitimately do is publish accurate, comprehensive, well-structured information about their products; ensure that their FDA-approved labeling is easily accessible and correctly formatted for AI indexing; engage in the structured feedback processes that AI companies have created for medical content correction; and monitor AI outputs systematically to detect errors early.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Structured Data and Schema Markup for Drug Pages<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">One underutilized tool is structured data markup for pharmaceutical content. The schema.org Drug schema allows webmasters to mark up drug information pages with machine-readable metadata specifying the drug&#8217;s indication, dosage form, manufacturer, FDA approval status, and related clinical information. While not all AI systems explicitly consume schema markup, the practice improves content parsability and may improve representation in retrieval-augmented AI systems.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Building a Pharma AI Monitoring Program: A Practical Framework<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A functional pharmaceutical AI monitoring program has several distinct components that map onto existing organizational functions rather than requiring entirely new infrastructure.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Step 1: Define the Query Universe<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The monitoring program begins with a structured set of queries that represent the range of questions patients, caregivers, and physicians are likely to ask about each drug. This query universe should include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Brand name queries (&#8216;What is Keytruda used for?&#8217;)<\/li>\n\n\n\n<li>Mechanism queries (&#8216;How does PD-1 inhibition work?&#8217;)<\/li>\n\n\n\n<li>Safety and side effect queries (&#8216;Does Jardiance cause urinary tract infections?&#8217;)<\/li>\n\n\n\n<li>Comparison queries (&#8216;Is Eliquis better than Xarelto?&#8217;)<\/li>\n\n\n\n<li>Generic and biosimilar queries (&#8216;Is there a generic version of Humira?&#8217;)<\/li>\n\n\n\n<li>Off-label queries (&#8216;Can Ozempic be used for PCOS?&#8217;)<\/li>\n\n\n\n<li>Cost and access queries (&#8216;Why is my insurance denying Dupixent?&#8217;)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The query universe should be refreshed regularly as new patient questions emerge, new clinical data is published, or new competitive products enter the market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Step 2: Systematic Cross-Platform Probing<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Each query in the universe should be submitted systematically across the major AI platforms on a regular cadence \u2014 weekly or biweekly for high-priority drugs, monthly for others. The responses should be logged, versioned, and compared across platforms and over time to identify:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Accuracy deviations from approved labeling<\/li>\n\n\n\n<li>Sentiment patterns (positive, negative, neutral)<\/li>\n\n\n\n<li>Share of voice relative to competitors<\/li>\n\n\n\n<li>Hallucination events (false claims not supported by any legitimate source)<\/li>\n\n\n\n<li>Source attribution patterns (what sources the model cites or appears to draw from)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Platforms like <a href=\"https:\/\/www.drugchatter.com\/monitoring\/\">DrugChatter<\/a> automate portions of this workflow, enabling brand teams to run structured probe sets across multiple AI systems and receive comparative reports without manual query submission at scale.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Step 3: Clinical and Regulatory Review of Flagged Outputs<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not every AI output deviation is a regulatory concern. A model that describes a drug&#8217;s mechanism slightly differently from the label without introducing safety risk requires a different response than a model that tells patients a drug has no drug interactions when the label lists several significant ones. A triage system that distinguishes safety-critical errors from brand accuracy issues from share-of-voice gaps is necessary to avoid alarm fatigue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The triage function typically involves medical affairs reviewers for clinical accuracy assessment and regulatory affairs reviewers for compliance implications. At companies with mature programs, this review is integrated into the pharmacovigilance workflow.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Step 4: Action Planning and Escalation Protocols<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">When a monitoring program identifies a significant AI output error \u2014 particularly one involving safety information \u2014 the question is what to do. The available options include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Publishing or updating accurate content that may be indexed and absorbed by retrieval-augmented models<\/li>\n\n\n\n<li>Using AI platform feedback mechanisms to flag medically inaccurate outputs (available through OpenAI&#8217;s API feedback tools and Google&#8217;s Search Quality reporting)<\/li>\n\n\n\n<li>Briefing medical information call center staff on the error pattern so they can address patient questions that may be downstream from AI misinformation<\/li>\n\n\n\n<li>Escalating to regulatory affairs for assessment of whether the error pattern constitutes a reportable event or requires label communication update<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The escalation protocol should be documented and approved before it is needed, not developed under pressure after a significant AI error is discovered.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">The Litigation Landscape: When AI Drug Misinformation Creates Legal Exposure<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pharmaceutical litigation involving AI-generated content is in its early stages, but the legal framework for pharmaceutical product liability and consumer protection law is well-developed and ready to absorb AI-specific claims.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Product Liability and the AI Intermediary Question<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Traditional pharmaceutical product liability holds manufacturers responsible for injuries caused by their drugs when the manufacturer failed to adequately warn about known risks. The learned intermediary doctrine typically places the warning obligation toward the prescribing physician rather than the patient directly.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AI search complicates this framework in ways that courts have not yet resolved. If a patient receives incorrect information about a drug&#8217;s risks from an AI system, and that incorrect information influences a healthcare decision that results in harm, the liability chain runs from the patient through the AI provider and potentially to the pharmaceutical manufacturer \u2014 depending on what the manufacturer knew, how the misinformation was generated, and whether the manufacturer took reasonable steps to correct it.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No court has yet issued a definitive ruling on pharmaceutical liability for AI-generated drug misinformation. But several personal injury plaintiff firms have flagged the theory as a developing area, and at least one pending class action involving AI health content (not yet disclosed in detail by the filing parties) includes pharmaceutical manufacturer co-defendants.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">FTC Disclosure and AI-Generated Drug Content<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Federal Trade Commission&#8217;s guidance on endorsements and testimonials applies to AI-generated content in the same way it applies to human-generated content. If a pharmaceutical company sponsors, directly or indirectly, AI-generated content about its product without disclosure, that constitutes a deceptive practice under the FTC Act.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This creates a constraint on the more aggressive strategies some pharmaceutical digital marketing teams have considered \u2014 using AI to generate large volumes of positive content about their products and seeding it into indexed sources that might influence model training. The legal and reputational risk of that strategy is substantial.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Competitive Intelligence Through AI Monitoring: What Your Competitors&#8217; AI Mentions Tell You<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">AI monitoring programs built to track a company&#8217;s own drugs produce a valuable secondary output: competitive intelligence. The same systematic query probing that reveals how ChatGPT describes a company&#8217;s drug in relation to its label also reveals how the model describes the competitor drug in the same category.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Detecting Competitor Weaknesses in AI-Generated Content<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If a competitor&#8217;s drug consistently receives negative sentiment in AI-generated responses \u2014 because the model is absorbing litigation coverage, FDA warning letter language, or patient forum complaints \u2014 that is a brand health signal for the competitor that the monitoring company can observe. If the competitor&#8217;s drug is being systematically confused with its generic equivalent in AI responses, that confusion may be affecting the competitor&#8217;s brand differentiation efforts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This competitive intelligence function does not require any active intervention. It is a natural output of systematic monitoring. A pharmaceutical brand team that probes &#8216;What are the best treatments for [condition]?&#8217; across five AI platforms, and tracks the response over 12 months, accumulates a competitive intelligence dataset about every drug mentioned in those responses.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">AI Share-of-Voice Benchmarking<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The operational metric that has emerged from early pharmaceutical AI monitoring programs is AI share of voice \u2014 the percentage of relevant AI-generated responses in a given therapeutic category that mention a specific drug by name, in a specific context. Tracking this metric over time and across platforms creates a brand health dashboard that has no equivalent in traditional media monitoring.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The metric is still being standardized. Different companies define the query universe differently, and the normalization of responses across platforms with different output formats is a methodological challenge. But the direction is clear: AI share of voice will be a standard pharmaceutical brand KPI within three to five years, and companies that begin building their monitoring infrastructure now will have a substantial data advantage over those that wait.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Pharmacovigilance in the Age of AI: What Regulators Are Watching<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA&#8217;s Sentinel System, which monitors post-market drug safety signals using electronic health records and claims data from more than 500 million patients, is the gold standard for systematic adverse event surveillance. Social media and now AI output monitoring represent a complementary, lower-fidelity but faster-moving signal stream that regulators and manufacturers are learning to use together.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can AI Outputs Be Used for Pharmacovigilance?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Directly, no \u2014 with important caveats. An AI model&#8217;s statement about a drug&#8217;s side effects is not itself a pharmacovigilance signal in the way that a patient-reported adverse event is. But AI outputs can be used as a leading indicator of patient question patterns, which in turn can direct pharmacovigilance teams toward emerging signals worth investigating in formal data sources.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If monitoring reveals that AI systems are consistently surfacing questions about a specific side effect that does not appear prominently in the drug&#8217;s label, that pattern is worth investigating. It may reflect the model absorbing pre-publication clinical literature, or patient forum discussions of real experiences not yet captured in formal adverse event reporting, or litigation discovery materials that have entered the public record.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The EMA&#8217;s Approach to AI in Drug Safety Surveillance<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The European Medicines Agency has been more proactive than the FDA in publishing guidance on digital and AI tools in pharmacovigilance. The EMA&#8217;s 2023 reflection paper on the use of digital and social media for pharmacovigilance endorsed the use of digital listening tools \u2014 including social media and patient-generated content \u2014 as supplementary adverse event signal detection sources, subject to validation requirements.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EMA guidance does not explicitly address AI output monitoring, but the framework it establishes \u2014 qualified signal detection from digital sources, with formal validation before regulatory action \u2014 is the right model for AI output monitoring as well.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Key Takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>AI systems including ChatGPT, Gemini, Claude, and Perplexity are now primary drug information sources for a meaningful share of patients and physicians, and what they say about branded drugs has brand health, patient safety, and regulatory compliance implications.<\/li>\n\n\n\n<li>LLM hallucinations about drug safety \u2014 including outdated label information, distorted adverse event frequencies, and incorrect drug interaction claims \u2014 represent real patient safety risks and potential regulatory exposure for pharmaceutical manufacturers.<\/li>\n\n\n\n<li>The FDA has not yet issued AI-specific drug content guidance, but existing promotional compliance, adverse event reporting, and pharmacovigilance frameworks create obligations that extend to AI-generated content manufacturers are aware of.<\/li>\n\n\n\n<li>AI share of voice \u2014 how often a drug is mentioned, in what context, and with what accuracy across major LLM platforms \u2014 is emerging as a standard pharmaceutical brand KPI.<\/li>\n\n\n\n<li>Systematic AI output monitoring programs require a defined query universe, regular cross-platform probing, clinical and regulatory triage of flagged outputs, and documented escalation protocols.<\/li>\n\n\n\n<li>Platforms like <a href=\"https:\/\/www.drugchatter.com\/monitoring\/\">DrugChatter<\/a> provide purpose-built infrastructure for pharmaceutical AI brand monitoring, enabling companies to track accuracy, sentiment, and share of voice across AI systems at scale.<\/li>\n\n\n\n<li>The competitive intelligence value of AI monitoring extends beyond a company&#8217;s own drug portfolio: systematic monitoring of category-level AI queries reveals competitor brand health dynamics, generic substitution patterns, and emerging patient concern signals.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">What is pharmaceutical AI monitoring and why do drug companies need it?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pharmaceutical AI monitoring is the systematic tracking of how large language models \u2014 including ChatGPT, Gemini, Claude, and Perplexity \u2014 represent a drug company&#8217;s products in response to patient, caregiver, and physician queries. Drug companies need it because AI search is now a primary information source for healthcare decisions, and what AI systems say about a drug influences patient adherence, physician perception, formulary dynamics, and regulatory exposure. Unlike traditional media, AI-generated content cannot be tracked with standard media monitoring tools \u2014 it requires structured query probing across platforms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can AI hallucinations about drug safety create FDA regulatory exposure?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Potentially, yes. While the FDA has not issued specific guidance on AI-generated drug content, the existing framework for adverse event reporting and pharmacovigilance does not exclude digital sources. If a pharmaceutical company&#8217;s monitoring program identifies that a major AI platform is providing systematically incorrect safety information about its drug \u2014 particularly information that contradicts the approved label \u2014 the company&#8217;s response (or non-response) to that knowledge may be relevant to its regulatory compliance posture. Regulatory attorneys in pharmaceutical promotional compliance are actively working through these implications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How do LLMs decide which drugs to recommend \u2014 branded or generic?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">LLMs do not have explicit recommendation algorithms for branded versus generic drugs. Their outputs reflect patterns in training data, which includes health journalism, clinical literature, patient forums, pharmacy benefit management content, and pharmaceutical company publications. In practice, models tend to surface cost-focused generic recommendations more frequently for off-patent molecules because that framing dominates the web content they were trained on. For branded drugs facing patent cliffs or biosimilar competition, this is a measurable share-of-voice risk that AI monitoring programs can track.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What queries should a pharmaceutical company use to monitor its AI brand presence?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A comprehensive AI monitoring query set for a pharmaceutical brand should include brand name queries, generic name queries, mechanism of action queries, indication queries, safety and side effect queries, competitor comparison queries, off-label queries, generic or biosimilar equivalence queries, and cost and access queries. The set should be updated regularly as new clinical data is published, label updates are made, or new patient questions emerge from support channels and social listening programs. The goal is to cover the full range of questions that real patients and physicians are likely to ask about the drug category.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How is AI share of voice different from traditional share of voice, and how is it measured?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Traditional pharmaceutical share of voice measures the proportion of category-level paid media, earned coverage, or digital traffic that a specific drug or brand captures. AI share of voice measures how often a drug is named, in what context, and with what accuracy in AI-generated responses to category-level queries across major LLM platforms. It is measured by running a standardized set of category queries \u2014 &#8216;What are the treatment options for [condition]?&#8217; being the simplest example \u2014 across platforms, logging all brand mentions in responses, and calculating each brand&#8217;s representation as a percentage of total mentions. Tools like <a href=\"https:\/\/www.drugchatter.com\/monitoring\/\">DrugChatter<\/a> automate this measurement and track it over time to identify trend shifts.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>When a patient types &#8216;Is Ozempic safe for people with pancreatitis?&#8217; into ChatGPT, the answer they receive is not written [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":461,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"modified_by":"DrugChatter","_links":{"self":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/comments?post=308"}],"version-history":[{"count":2,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/308\/revisions"}],"predecessor-version":[{"id":462,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/308\/revisions\/462"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media\/461"}],"wp:attachment":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media?parent=308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/categories?post=308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/tags?post=308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}